Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The molecular profile of mucosal melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Global microRNA profiling of metastatic conjunctival melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

This study investigates the prognostic and predictive value of YKL-40 in stage IIB-III melanoma patients who were randomized to adjuvant interferon α-2b (IFN) or observation. Serum YKL-40 was determined postoperatively in patients from the Nordic IFN Trial (n=602), EORTC 18952 (n=246), and EORTC 18991 (n=386) (EORTC, European Organisation for Research and Treatment of Cancer). YKL-40 protein expression was determined in 300 tissue sections of primary melanoma or lymph node metastases from 204 Danish patients from the Nordic IFN Trial. Multivariate Cox analysis (including sex, age, stage, ulceration, YKL-40) showed that elevated baseline YKL-40 level was associated with shorter overall survival (OS) in observation groups from the Nordic IFN Trial and EORTC 18952 [hazard ratio (HR)=1.33; 95% confidence interval (CI) 1.01-1.74; P=0.04], but not in the interferon groups (1-year IFN: HR=0.97; 95% CI 0.76-1.25; P=0.83; 2-years IFN: HR=1.06; 95% CI 0.83-1.34; P=0.64). During follow-up, increases in YKL-40 were significantly associated with shorter OS, but not with recurrence-free survival in univariate analysis. YKL-40 expression was stronger in tumor-associated macrophages than melanoma cells in primary melanoma. High YKL-40 expression in macrophages in lymph node metastases was associated with shorter OS in the observation group (HR=2.76; 95% CI: 1.13-6.76, P=0.02), but not in the interferon-treated groups. YKL-40 was an independent prognostic biomarker of OS in melanoma patients stage IIB-III. High serum YKL-40 in poor-prognosis patients may originate from macrophages in the tumor microenvironment and the melanoma cells. Furthermore, we hypothesize that elevated serum YKL-40 after surgery may predict the efficacy of adjuvant IFN treatment.

Original languageEnglish
JournalMelanoma Research
Volume26
Issue number4
Pages (from-to)367-76
Number of pages10
ISSN0960-8931
DOIs
Publication statusPublished - Aug 2016

    Research areas

  • Journal Article

ID: 49700392